108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
炎症相关蛋白与原发性卵巢功能不全风险之间的遗传关联及药物靶点探索
Authors Wang C , Lin XH, Yang XJ
Received 6 May 2025
Accepted for publication 3 October 2025
Published 9 October 2025 Volume 2025:18 Pages 14023—14037
DOI https://doi.org/10.2147/JIR.S538776
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Ning Quan
Chong Wang,1 Xian-Hua Lin,2 Xiao-Jing Yang1
1Department of Reproductive Medicine, Hangzhou Women’s Hospital, Hangzhou, Zhejiang Province, People’s Republic of China; 2Women and Children’s Medical Center, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen, Guangdong Province, People’s Republic of China
Correspondence: Xian-Hua Lin, Women and Children’s Medical Center, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen, Guangdong Province, People’s Republic of China, Email xl_1290@126.com Xiao-Jing Yang, Department of Reproductive Medicine, Hangzhou Women’s Hospital, Hangzhou, Zhejiang Province, People’s Republic of China, Email moving_yang@163.com
Purpose: Primary ovarian insufficiency (POI) exhibits ovarian dysfunction characteristics, which develops from diminished ovarian reserve (DOR). However, the pathogenesis remains unclear. In this study, we aimed to analyze the causal relationship between inflammation-related proteins and the occurrence of POI at the genetic level, and to identify potential druggable gene targets from inflammation-related genes.
Patients and Methods: We conducted a Mendelian randomization (MR) analysis to explore causal association for inflammation-related proteins and POI. Genetic instruments for 91 inflammation-related proteins were derived from the Olink® Target Inflammation panel with totally 14,824 European participants. Summary statistics for 424 POI cases and 118,796 controls were acquired from the FinnGen. Furthermore, by combining the Olink results from DOR patients with MR results, we highlighted five inflammation-related moleculars in ovarian aging. All were validated by Western-blot and RT-PCR in the POI model. Bioinformatics analysis was performed to reveal potential pathways, and potential drug screening was performed by the DGIdb database.
Results: Via inverse-variance weighted (IVW) method, our study identified two proteins, CXCL10 and CX3CL1 might exert protective effects against POI; whereas IL-18R1, IL-18, MCP-1, and CCL28 might increase the risk of POI. Moreover, Wald ratio analyses highlighted additional protective proteins, such as IL-17C, TRANCE, uPA, LAP TGF-β 1, and CXCL9; along with risk proteins, including TNFSF14, CD40, IL-24, ARTN, LIF-R, and IL-2RB. Meanwhile, MCP-1/CCL2, TGFB1, ARTN, and LIFR were significantly changed in the POI model, which converged in the oncostatin M signaling pathway. Notably, gene-drug analysis identified CCL2 and TGFB1 as potential therapeutic targets, whereas genistein and melatonin were prioritized as potential drugs for POI treatment.
Conclusion: Our study highlights the causal role of specific inflammation-related proteins in POI, advancing our understanding of its etiology, and further extends the therapeutic options for improving ovarian function and delaying POI onset.
Keywords: primary ovarian insufficiency, inflammation-related proteins, mendelian randomization, gene-drug analysis
1Department of Reproductive Medicine, Hangzhou Women’s Hospital, Hangzhou, Zhejiang Province, People’s Republic of China; 2Women and Children’s Medical Center, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen, Guangdong Province, People’s Republic of China
Correspondence: Xian-Hua Lin, Women and Children’s Medical Center, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen, Guangdong Province, People’s Republic of China, Email xl_1290@126.com Xiao-Jing Yang, Department of Reproductive Medicine, Hangzhou Women’s Hospital, Hangzhou, Zhejiang Province, People’s Republic of China, Email moving_yang@163.com
Purpose: Primary ovarian insufficiency (POI) exhibits ovarian dysfunction characteristics, which develops from diminished ovarian reserve (DOR). However, the pathogenesis remains unclear. In this study, we aimed to analyze the causal relationship between inflammation-related proteins and the occurrence of POI at the genetic level, and to identify potential druggable gene targets from inflammation-related genes.
Patients and Methods: We conducted a Mendelian randomization (MR) analysis to explore causal association for inflammation-related proteins and POI. Genetic instruments for 91 inflammation-related proteins were derived from the Olink® Target Inflammation panel with totally 14,824 European participants. Summary statistics for 424 POI cases and 118,796 controls were acquired from the FinnGen. Furthermore, by combining the Olink results from DOR patients with MR results, we highlighted five inflammation-related moleculars in ovarian aging. All were validated by Western-blot and RT-PCR in the POI model. Bioinformatics analysis was performed to reveal potential pathways, and potential drug screening was performed by the DGIdb database.
Results: Via inverse-variance weighted (IVW) method, our study identified two proteins, CXCL10 and CX3CL1 might exert protective effects against POI; whereas IL-18R1, IL-18, MCP-1, and CCL28 might increase the risk of POI. Moreover, Wald ratio analyses highlighted additional protective proteins, such as IL-17C, TRANCE, uPA, LAP TGF-β 1, and CXCL9; along with risk proteins, including TNFSF14, CD40, IL-24, ARTN, LIF-R, and IL-2RB. Meanwhile, MCP-1/CCL2, TGFB1, ARTN, and LIFR were significantly changed in the POI model, which converged in the oncostatin M signaling pathway. Notably, gene-drug analysis identified CCL2 and TGFB1 as potential therapeutic targets, whereas genistein and melatonin were prioritized as potential drugs for POI treatment.
Conclusion: Our study highlights the causal role of specific inflammation-related proteins in POI, advancing our understanding of its etiology, and further extends the therapeutic options for improving ovarian function and delaying POI onset.
Keywords: primary ovarian insufficiency, inflammation-related proteins, mendelian randomization, gene-drug analysis